Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment.
about
Recommendations for the Management of Herpes ZosterAcyclovir suppression to prevent clinical recurrences at delivery after first episode genital herpes in pregnancy: an open-label trialFDA labeling system for drugs in pregnancy.Varicella-zoster virus: atypical presentations and unusual complications.Review of antiviral therapy for herpes labialis, genital herpes and herpes zoster.Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir.Progress in meeting today's demands in genital herpes: an overview of current management.Neonatal herpes simplex infection.Complete the Following Statement: Industry-Sponsored Antiepileptic Drug Pregnancy Registries Provide Information that is Beneficial to:: PatientsDoctorsThe SponsorAll of the AboveNone of the AboveCannot Respond Due to Risk of COIAcyclovir suppression to prevent recurrent genital herpes at delivery.Headache in pregnancy: a nuisance or a new sense?Treatment of migraine headaches with sumatriptan in pregnancy.Migraine headaches and preeclampsia: an epidemiologic review.Prophylactic treatment of bipolar disorder in pregnancy and breastfeeding: focus on emerging mood stabilizers.Triptans in pregnancy.Antiherpetic medication use and the risk of gastroschisis: findings from the National Birth Defects Prevention Study, 1997-2007.Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohortsHerpes simplex virus infection in pregnancy and in neonate: status of art of epidemiology, diagnosis, therapy and preventionTreatment of cluster headache in pregnancy and lactation.Maternal self-reported genital tract infections during pregnancy and the risk of selected birth defects.Managing sexually transmitted infections in pregnant women.Varicella zoster: an update on current treatment options and future perspectives.European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment.Characterization of a proteolytically stable D-peptide that suppresses herpes simplex virus 1 infection: implications for the development of entry-based antiviral therapy.Acyclovir exposure and birth defects: an important advance, but more are needed.Sumatriptan: what do we know about fetal risks?Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan.Evidence-based assessment of pregnancy outcome after sumatriptan exposure.5HT1B/1D agonists.Transplacental passage of lamotrigine in a human placental perfusion system in vitro and in maternal and cord blood in vivo.Adverse pregnancy outcome in women exposed to acyclovir during pregnancy: a population-based observational study.
P2860
Q28315869-C7CA515F-548B-4866-8D35-18D2A45E7163Q28345700-25473D03-6034-4A6F-AADF-0C4C9DA4A043Q34449499-407029E1-F8AE-461F-8708-2B874A36F92BQ34527694-DB244B49-E1A6-48CF-B1D3-E29530BE94ABQ34551831-D107C221-8A24-43B6-9148-40DC1CD0A921Q34918273-EE0D351C-67F5-408B-8B65-85B461F0B1CCQ34918299-660CC6D0-288E-4B29-B525-95FCBC9DBDA8Q35545367-26FD6B86-3AFC-44A5-9C32-5E6E38DCB058Q35562360-44BB6112-0DCF-4F5B-8901-8A5624670FE5Q35614637-FBDFF2FA-6CC9-44A9-9054-178CCCF1007CQ35837966-F65D10C0-A93B-4DDD-A4B2-1FDF344FDEFCQ35865451-C5EE059E-8A50-43EC-B021-7D2E710F46D4Q36462139-18444B36-89D4-4BB6-917A-08138AA3FAECQ36476778-C3049E60-0855-43E1-883A-0D8E7A7F9B86Q36817033-0269EF92-7B45-4B14-A4FC-F5AF0B128143Q36950122-C1A71757-19B4-4A18-8AAD-F3A157B36247Q37138858-25732124-A680-43A4-A092-986DA7375CA9Q37164885-007819DC-2F07-4456-8403-FBBA8B1AD50AQ37377970-3A94E19F-ED71-4016-AC00-7E34C077AD4EQ37851375-C37BA547-D633-45D8-AD34-4ED90364185AQ38007203-23BA4332-CBDD-4303-BB0B-AF5AF6613A3FQ38167380-12EC0694-71EF-48FF-912D-FC8BF06FEB9BQ38942259-A9B5AF76-459E-47CE-AAD5-1BB32810EFE2Q41646280-DBC8AA5E-10A4-41CB-AF69-0E3C13E3A0AEQ42870200-CDAAA4CC-8AEA-4F97-B214-59178BB18589Q43544057-3B6D8736-1243-48DB-9A85-C9CC0716A0CAQ43586097-8186F427-8D65-4E4B-8239-E672C2E2CFC4Q43989452-1EF46746-96E5-4FAE-A1E9-62B9F816B56BQ44202492-31719189-EC7D-48CF-9201-DA6849114F74Q44334635-6822EA8A-6CC5-4AB9-BB02-5C05714A0110Q44500097-0FEC5762-54B2-4882-8801-8C6175A59E45
P2860
Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Monitoring pregnancy outcomes ...... maceutical company commitment.
@en
Monitoring pregnancy outcomes ...... maceutical company commitment.
@nl
type
label
Monitoring pregnancy outcomes ...... maceutical company commitment.
@en
Monitoring pregnancy outcomes ...... maceutical company commitment.
@nl
prefLabel
Monitoring pregnancy outcomes ...... maceutical company commitment.
@en
Monitoring pregnancy outcomes ...... maceutical company commitment.
@nl
P2093
P1476
Monitoring pregnancy outcomes ...... maceutical company commitment.
@en
P2093
C R Heffner
E B Andrews
P S Tennis
R Reiff-Eldridge
S A Ephross
P304
P356
10.1016/S0002-9378(00)70506-0
P407
P433
P577
2000-01-01T00:00:00Z